Reneo Pharmaceuticals, Inc.

NasdaqGM:RPHM Stock Report

Market Cap: US$60.8m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Reneo Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RPHM Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Sep 24BuyUS$144,738BML Capital Management, LLCCompany9,834.6US$14.96
18 Sep 24BuyUS$76,237BML Capital Management, LLCCompany5,610.6US$14.00
16 Sep 24BuyUS$484,344BML Capital Management, LLCCompany35,892.3US$13.97
14 Aug 24BuyUS$380,598BML Capital Management, LLCCompany27,182.6US$14.13
14 May 24BuyUS$639,578BML Capital Management, LLCCompany41,428.1US$15.60

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RPHM?
Owner TypeNumber of SharesOwnership Percentage
Private Companies134,0840.401%
General Public1,575,8104.71%
Individual Insiders1,592,0984.76%
Hedge Funds8,622,77125.8%
Institutions9,454,15028.3%
VC/PE Firms12,049,89536%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 91.68% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.3%
New Enterprise Associates, Inc.
4,785,494US$8.7m0%0.43%
10.3%
BML Capital Management, LLC
3,457,395US$6.3m29.4%3.21%
8.81%
Tang Capital Management, LLC
2,946,260US$5.4m-1.67%0.41%
8.72%
Highbridge Capital Management, LLC
2,915,376US$5.3m6.53%0.13%
8.07%
Abingworth LLP
2,698,957US$4.9m0%1.26%
7.58%
RiverVest Venture Management LLC
2,534,220US$4.6m0%63.4%
6.73%
Octagon Capital Advisors LP
2,250,000US$4.1m0%0.58%
6.08%
Lundbeckfonden BioCapital
2,031,224US$3.7m0%0.05%
3.05%
Braden Leonard
1,020,769US$1.9m0%no data
2.65%
Aisling Capital Management LP
886,075US$1.6m0%0.6%
2.64%
The Vanguard Group, Inc.
882,104US$1.6m-9.14%no data
1.64%
Nantahala Capital Management, LLC
547,804US$997.0k0%0.08%
1.63%
Vestal Point Capital, LP
545,000US$991.9k84.5%0.06%
1.48%
Michael Grey
494,762US$900.5k0%no data
1.34%
Aldebaran Capital, LLC
447,616US$814.7k12.9%0.69%
1.32%
Renaissance Technologies LLC
442,200US$804.8k-25.5%no data
1.22%
Acuitas Investments, LLC
406,209US$739.3k0.53%0.24%
0.88%
BlackRock, Inc.
293,651US$534.4k-70.5%no data
0.6%
Geode Capital Management, LLC
201,036US$365.9k-39.6%no data
0.56%
Eaton Vance Management
186,357US$339.2k-7.64%no data
0.49%
Opaleye Management Inc.
165,000US$300.3k0%0.04%
0.4%
The Grey 2014 Irrevocable Childrens Trust
134,084US$244.0k0%no data
0.39%
BMO Asset Management Corp.
130,743US$238.0k-2.45%no data
0.38%
Goldman Sachs Group, Investment Banking and Securities Investments
126,466US$230.2k226%no data
0.35%
Northern Trust Global Investments
117,860US$214.5k5.1%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/06 23:17
End of Day Share Price 2024/10/04 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Reneo Pharmaceuticals, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason ZemanskyBofA Global Research
Xiaodong ZhangH.C. Wainwright & Co.